Atorvastatin loaded glycerosomal patch as an effective transdermal drug delivery: optimization and evaluation.

IF 3 Q2 PHARMACOLOGY & PHARMACY Therapeutic delivery Pub Date : 2024-10-21 DOI:10.1080/20415990.2024.2408218

Pravin Patil, Mrunal Rahangdale, Krutika Sawant

引用次数: 0

Abstract

Aim: The study explores glycerosomes as effective vesicular systems for transdermal delivery of atorvastatin (ATO) to overcome drawbacks related to its oral administration.Methodology: The objectives of this study were to formulate, by thin-film hydration method, optimize using definitive screening design and evaluate ATO-loaded glycerosomes (ATOG) which were then incorporated into patch followed by the evaluation of glycerosomes containing different concentration of glycerol.Results & discussion: Vesicle size, Polydispersity index (PDI), zeta potential, entrapment efficiency and loading capacity of spherical ATOG (0-30%w/w) showed 137.3-192d.nm, 0.292-0.403, -3.81 to-6.76mV, 80.03-92.77% and 5.80-6.40%, respectively. In-vitro release study showed sustained release, increased skin permeability and better cell viability than pure drug. ATOG patches showed greater skin permeability than pure drug and ATO-liposomal patches.Conclusion: The study concludes that ATOGs are promising for effective transdermal delivery.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿托伐他汀负载甘油囊贴片作为一种有效的透皮给药：优化与评估。

目的：本研究探讨了甘油囊作为阿托伐他汀（ATO）透皮给药的有效囊泡系统，以克服口服给药的相关缺点：本研究的目的是通过薄膜水合法配制、使用确定性筛选设计进行优化并评估负载 ATO 的甘油囊（ATOG），然后将其纳入贴片，接着评估含有不同浓度甘油的甘油囊：球形 ATOG（0-30%w/w）的囊泡大小、多分散指数（PDI）、ZETA电位、夹持效率和负载能力分别为 137.3-192d.nm、0.292-0.403、-3.81-6.76mV、80.03-92.77% 和 5.80-6.40%。体外释放研究显示，与纯药物相比，ATOG 贴片具有持续释放、皮肤渗透性更强和细胞存活率更高的特点。ATOG 贴片的皮肤渗透性高于纯药物和 ATO 脂质体贴片：该研究得出结论，ATOGs 有望实现有效的透皮给药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

0.00%

发文量

期刊介绍： Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.